Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 9, 2019

View Archived Issues

An inclusive look at the microbiome

NGM reports promising interim results from ongoing phase II study of aldafermin in NASH

Xoc Pharmaceuticals launches phase I study of XC101-D13H

New mouse model of diabetic cystopathy described

Discovery of novel potent fully human FVIII mimetic BiAb, KY-1049

Selepressin does not improve vasopressor- and ventilator-free days in patients with septic shock

Preliminary data presented from phase I/II ASPIRO study of AT-132

MinL4.0 RSV: a synthetic, live-attenuated vaccine against respiratory syncytial virus

MTPS-9579A dose-dependently inactivates airway tryptase for the treatment of asthma

FDA approves Wilate for hemophilia A

Tezepelumab reduces activation of matrix remodeling and inflammatory pathways

Scenesse wins approval in U.S. for erythropoietic protoporphyria

GSK and Lyell Immunopharma collaborate to improve cell therapies for cancer

Faron receives DMC feedback for phase I/II MATINS trial of Clevegen

U.S. researchers patent ATR kinase inhibitors

University of California discloses new VLA-2 antagonists

Pfizer identifies antibacterial agents

Hinova Pharmaceuticals details compounds for cancer

New ALK kinase inhibitors revealed in University of Michigan patent

New CRISPR-Cas9 variant may boost gene-editing precision

AZD-4205 begins phase I/II study in Korea for peripheral T-cell lymphoma

Incyte initiates phase I/II study of INCB-001158 with daratumumab in multiple myeloma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...